US 12280046
Melanocortin subtype-2 receptor (MC2R) antagonist for the treatment of disease
granted A61KA61K31/496A61K31/573
Quick answer
US patent 12280046 (Melanocortin subtype-2 receptor (MC2R) antagonist for the treatment of disease) held by CRINETICS PHARMACEUTICALS, INC. expires Mon Apr 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- CRINETICS PHARMACEUTICALS, INC.
- Grant date
- Tue Apr 22 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Apr 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 18
- CPC classes
- A61K, A61K31/496, A61K31/573, A61K9/0053, A61P